
Sign up to save your podcasts
Or


In this episode, we are joined by two lymphoma experts - Victoria Nachar, PharmD, BCOP and Tycel Phillips MD - to discuss the use of bispecific antibodies in Diffuse Large B-Cell Lymphoma (DLBCL)! Stay tuned for an exciting episode where we discuss the data, their possible role in therapy, and what questions and controversies remain.
Relevant Articles:
Review on Design of Bispecifics - https://pubmed.ncbi.nlm.nih.gov/25728220/
Epcoritamab - https://pubmed.ncbi.nlm.nih.gov/36548927/
Glofitamab - https://pubmed.ncbi.nlm.nih.gov/36507690/
Mosunetuzumab - https://pubmed.ncbi.nlm.nih.gov/34914545/
Odronextamab - https://pubmed.ncbi.nlm.nih.gov/35366963/
CRS and ICANS grading - https://pubmed.ncbi.nlm.nih.gov/30592986/
By Bernard Marini, Anthony Perissinotti, et al.4.5
3030 ratings
In this episode, we are joined by two lymphoma experts - Victoria Nachar, PharmD, BCOP and Tycel Phillips MD - to discuss the use of bispecific antibodies in Diffuse Large B-Cell Lymphoma (DLBCL)! Stay tuned for an exciting episode where we discuss the data, their possible role in therapy, and what questions and controversies remain.
Relevant Articles:
Review on Design of Bispecifics - https://pubmed.ncbi.nlm.nih.gov/25728220/
Epcoritamab - https://pubmed.ncbi.nlm.nih.gov/36548927/
Glofitamab - https://pubmed.ncbi.nlm.nih.gov/36507690/
Mosunetuzumab - https://pubmed.ncbi.nlm.nih.gov/34914545/
Odronextamab - https://pubmed.ncbi.nlm.nih.gov/35366963/
CRS and ICANS grading - https://pubmed.ncbi.nlm.nih.gov/30592986/

38,515 Listeners

25,764 Listeners

87,155 Listeners

112,032 Listeners

56,516 Listeners

187 Listeners

10,203 Listeners

7,231 Listeners

51 Listeners

8 Listeners

15,835 Listeners

10,711 Listeners

48 Listeners

192 Listeners

618 Listeners